There is no verified September 2026 FDA update changing hormonal acne treatment. What is new is stronger—but still incomplete—dermatology evidence supporting spironolactone for some adult women. Hormonal acne is acne influenced by androgen hormones, often appearing persistently on the lower face, jawline, or neck. Current evidence supports several hormone-targeting options, but none is right for every patient.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the original research from NIH — Use this page to review the original research.
- Read the original research from NIH — Use this page to review the original research.
Table of Contents
- Has the FDA changed Winlevi's approval?
- What do current guidelines recommend?
- How strong is the spironolactone evidence?
- Are compounded topical hormones established alternatives?
- What should patients do with this information?
Has the FDA changed Winlevi's approval?
No new September 2026 FDA action is established in the available federal record. The current DailyMed label is dated January 2, 2025, and still lists Winlevi's initial U.S. approval as 2020.
Winlevi contains clascoterone 1%, a topical androgen-receptor inhibitor. It is labeled for acne vulgaris in patients aged 12 and older and is applied twice daily. This distinction matters because a recent article or study is not an FDA approval or label change. Readers should check the federal label before treating reports of a "new FDA update" as confirmed.
What do current guidelines recommend?
The American Academy of dermatology conditionally recommends three hormone-related options: topical clascoterone, combined oral contraceptives, and oral spironolactone. A conditional recommendation means treatment depends on the patient's needs, risks, preferences, and other acne therapies—not that everyone should receive it.
The AAD acne guideline also favors combining topical treatments that work in different ways. It advises limiting oral antibiotics and using benzoyl peroxide alongside them to reduce antibiotic-resistance risk. A practical treatment discussion may therefore cover:.
- Where the acne appears and how long it has persisted
- Which topical treatments have already been tried
- Whether pregnancy precautions affect the available choices
- Whether antibiotics can be avoided or used for a limited role
- Which side effects or individual risks require screening
How strong is the spironolactone evidence?
Spironolactone has the clearest new evidence among the established oral hormonal options. A 2025 randomized-trial meta-analysis found that it increased the odds of treatment success 2.51-fold versus placebo or doxycycline in adult women with moderate-to-severe acne. That result supports spironolactone particularly when acne appears hormonally driven.
It does not prove that the medicine will work for every woman or that it should replace all topical treatments. A 2026 systematic review examined 13 studies involving 1,335 patients treated with spironolactone or metformin. Both appeared promising, but the review's authors called for stronger controlled randomized comparisons, so the evidence is encouraging rather than final.
Are compounded topical hormones established alternatives?
Not yet. A January 2026 review found limited and sometimes conflicting evidence for topical spironolactone, covering only 193 patients across six studies. Neither topical spironolactone nor topical flutamide is FDA-approved for acne.
Both require extemporaneous compounding, meaning a pharmacy prepares the formulation rather than dispensing an FDA-approved acne product in a standard marketed form. Patients should not assume that applying spironolactone to the skin provides the same evidence, dosing certainty, or regulatory status as oral spironolactone. Clascoterone remains the FDA-approved topical androgen-receptor inhibitor identified in the current label.
What should patients do with this information?
Persistent jawline, lower-face, or neck acne may justify a conversation about hormonal treatment. The AAD identifies combined oral contraceptives and spironolactone as options for women with this pattern. Spironolactone requires pregnancy precautions and clinician screening for individual risks.
Winlevi can cause local irritation, while its label warns of possible hypothalamic-pituitary-adrenal axis suppression—a reduction in the body's normal stress-hormone signaling. Systemic absorption risk may rise when Winlevi is used for a long time, over large areas, or beneath an occlusive covering. Pediatric patients may be more susceptible, so the prescribed amount, treatment area, and application method matter.
You Might Also Like
- What Is New With Remedies and Acne in August 2026? Latest FDA and dermatology sources and Key Takeaways
- What Is New With Lifestyle and Acne in August 2026? Latest FDA and dermatology sources and Key Takeaways
- What Is New With Jawline Acne in August 2026? Latest FDA and dermatology sources and Key Takeaways